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Abstract
Background: The two main mechanisms of resistance to EGFR tyrosine kinase inhibitors (TKIs) in non-small cell
lung cancer (NSCLC) are the occurrence of T790M secondary mutation in the kinase domain of EGFR and MET
amplification. The aim of the present study was to test whether early changes of 18F-fluorodeoxyglucose (18F-FDG)
uptake in animal models bearing erlotinib-resistant NSCLC may have different imaging patterns of response to
erlotinib depending on the molecular mechanisms underlying resistance.
Animal tumor models were developed using NSCLC H1975 cells bearing the T790M mutation and H1993 cells with
MET amplification. Nude mice bearing erlotinib-resistant H1975 and H1993 xenografts (four animals for each cell
line and for each treatment) were subjected to 18F-FDG PET/CT scan before and immediately after treatment
(50 mg/kg p.o. for 3 days) with erlotinib, WZ4002, crizotinib, or vehicle. A three-dimensional region of interest
analysis was performed to determine the percent change of 18F-FDG uptake in response to treatment. At the end
of the imaging studies, tumors were removed and analyzed for glycolytic and mitochondrial proteins as well as
levels of cyclin D1.
Results: Imaging studies with 18F-FDG PET/CT in H1975 tumor-bearing mice showed a reduction of 18F-FDG uptake
of 25.87 % ± 8.93 % after treatment with WZ4002 whereas an increase of 18F-FDG uptake up to 23.51 % ± 9.72 %
was observed after treatment with erlotinib or vehicle. Conversely, H1993 tumors showed a reduction of 18F-FDG
uptake after treatment with both crizotinib (14.70 % ± 1.30 %) and erlotinib (18.40 % ± 9.19 %) and an increase of
tracer uptake in vehicle-treated (56.65 % ± 5.65 %) animals. The in vivo reduction of 18F-FDG uptake was always
associated with downregulation of HKII and p-PKM2 Tyr105 glycolytic proteins and upregulation of mitochondrial
complexes (subunits I–IV) in excised tumors.
Conclusions: 18F-FDG uptake is a reliable imaging biomarker of T790M-mediated resistance and its reversal in
NSCLC whereas it may not be accurate in the detection of MET-mediated resistance.
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Background
Non-small cell lung cancer (NSCLC) is the leading cause
of cancer-related deaths in the world, showing only lim-
ited responsiveness to conventional anticancer agents.
The development of molecularly targeted agents and in
particular of tyrosine kinase inhibitors (TKIs) of the
epidermal growth factor receptor (EGFR) provided alter-
native strategies for treating this disease [1]. Currently,
advanced NSCLC patients are candidates to first-line
therapy with EGFR TKIs such as gefitinib and erlotinib
if their tumors bear activating mutations of EGFR that
have been recognized as the major determinant of effect-
ive tumor response to these targeted agents [2]. A high
rate of response to EGFR TKIs was indeed found in
patients with advanced EGFR-mutant NSCLC resulting
in an improvement of progression-free (PFS) and overall
(OS) survival of these patients [3]. The clinical efficacy
of gefitinib or erlotinib is however ultimately limited by
the development of acquired resistance to EGFR TKIs in
virtually all NSCLC patients with activating mutations of
EGFR who initially respond to therapy [4, 5]. About half
of resistant tumors develop T790M secondary mutations
in EGFR which prevent an effective inhibition by EGFR
TKIs [6, 7] whereas an additional 15–20 % of tumors
undergoes amplification of MET receptor tyrosine kinase
[8] which causes a lateral activation of EGFR signaling
cascade despite receptor inhibition.
18F-Fluorodeoxyglucose (18F-FDG) and positron emission
tomography/computed tomography (PET/CT) has been
successfully employed in the diagnosis, staging, and treat-
ment monitoring in NSCLC patients [9, 10]. The rationale
to use 18F-FDG in the detection and staging of NSCLC re-
sides in the fact that this tumor, as many other malignan-
cies, has an oncogene-driven glycolytic phenotype that
implies a high glucose demand due to an inefficient energy
production and the consequent dependence of cancer cells
from blood glucose supply. The rationale to use 18F-FDG in
the assessment of tumor response to therapy relies on the
fact that conventional cytotoxic agents, by inducing cell
death, cause a reduction of cell viability and glucose de-
mand with a consequent decrease of 18F-FDG uptake that
may precede tumor shrinkage as assessed by morphovolu-
metric criteria. Previous studies in NSCLC patients also
showed an early (2–14 days) reduction of 18F-FDG uptake
in response to treatment with EGFR TKIs [11–14] that was
predictive of morphovolumetric tumor response, PFS, and
OS. In sensitive NSCLC cells, the rapid reduction of 18F-
FDG uptake in response to EGFR TKIs was mainly corre-
lated with the inhibition of the PI3K/AKT pathway, reduc-
tion of hexokinase activity, and downregulation of glucose
transporters [15] that largely preceded any measurable
changes in the percentage of cells undergoing apoptosis. In
our previous studies, we showed that the inhibition of
EGFR signaling in NSCLC cells inhibits aerobic glycolysis
and restores oxidative phosphorylation through the con-
certed downregulation of hexokinase II (HKII) and pyru-
vate kinase M2 phosphorylated at Tyr105 (p-PKM2
Tyr105) and upregulation of mitochondrial complexes
(OXPHOS) [16]. In particular, the selective inhibition of the
AKT pathway in NSCLC cells resulted in the upregulation
of OXPHOS mediated by peroxisome proliferator-activated
receptor-γ coactivator-1α (PGC-1α) and increased levels of
ATP whereas the parallel downregulation of the ERK1/2
pathway reduced the glycolytic cascade and lactate levels.
Notably, NSCLC cells resistant to first-generation EGFR
TKIs showed a differential metabolic response to erlotinib
depending on the specific mechanism causing such resist-
ance. On the basis of these observations, here, we tested
whether early changes of the 18F-FDG uptake in animal
models bearing erlotinib-resistant NSCLC may have differ-
ent imaging patterns of response to erlotinib depending on
the molecular mechanism underlying resistance. Further-
more, we tested whether imaging findings may reflect
tumor levels of selected markers of energy metabolism.
Methods
Animal tumor models and treatment
All animal experimental procedures were conducted in ac-
cordance with Italian law for animal protection and were
approved by the Italian Ministry of Health-Animal Welfare
Direction (Protocol No. DGSAF21940-A-16/11/2013).
Female BALB/c (nu/nu) mice, 6 weeks old, weighing 15–
20 g were purchased from Charles River Laboratories
(Milan, Italy). Two NSCLC cell lines were obtained from
the American Type Culture Collection. In particular,
H1975 cells bear an activating point mutation in exon 21
(L858R) and also harbor the T790M mutation in the kinase
domain of EGFR [17]. Despite the T790M-mediated resist-
ance, H1975 cells remain EGFR-driven. H1993 cells are re-
ported to have a high level of MET gene amplification (15
copy numbers) [18, 19] and wild-type EGFR, thus showing
resistance to erlotinib [8]. All cells were grown in Roswell
ParkMemorial Institute (RPMI)medium supplementedwith
10 % fetal bovine serum, 100 IU/mL penicillin, and 50 μg/
mL streptomycin in a humidified incubator with 5 % CO2
at 37 °C, and then, 5–10 × 106 cells were resuspended in
200 μl RPMI medium and injected s.c. into the flank of
nude mice. When tumors reached a mean volume of
approximately 100 mm3, animals were randomized into
treatment groups (four animals for each cell line and for
each treatment) and subjected to imaging studies. Tumor-
bearing animals were treated daily for 3 days by oral gavage
with 50 mg/kg of erlotinib, WZ4002 [20, 21] (an irrevers-
ible EGFR TKI with a higher affinity for T790M mutant
EGFR than for wild-type EGFR), crizotinib [22, 23] (a MET
inhibitor), or vehicle as described in Fig. 1.
Two additional subgroups of H1975- and H1993-
tumor-bearing animals underwent longitudinal studies
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and were treated with 100 mg/kg erlotinib, WZ4002,
crizotinib, or vehicle for 9 days. Tumor size was mea-
sured daily by caliper, and volume was determined using
the following formula: volume = 0.5 × greatest diam-
eter × (shortest diameter)2.
Imaging studies with 18F-FDG and small-animal PET/CT
Each animal underwent a baseline and a post-treatment
scan using a small-animal PET/CT scanner (eXplore
Vista Pre-Clinical PET Scanner GE Healthcare). After
fasting for 8 h, animals received 7.4 MBq of 18F-FDG by
i.v. injection through the tail vein. Animals were anes-
thetized using 2 % isoflurane and then subjected to PET/
CT scan at 60 min post-injection.
Body temperature of the animals was held constant
during tracer biodistribution and imaging studies by
heating pad or heat lamp. One bed position including
the tumor was scanned, and CT images were acquired
with the x-ray source set at 35 kVp and 200 μA for
10 min followed by PET image acquisition for 20 min.
After acquisition, the images were reconstructed by a
combined algorithm based on Fourier rebinning (FORE)
followed by 2D iterative image reconstruction using
ordered-subset expectation maximization (OSEM). The
reconstructed images had a matrix size of 175 × 175 and
a voxel size of 0.3875 × 0.3875 × 0.7750 mm3. PET
images were corrected for decay and converted to SUV.
No statistically significant change of animal weight was
observed after treatment. PET/CT data were transferred
in DICOM format to an OsiriX workstation (Pixmeo,
Switzerland). Three-dimensional regions of interest were
drawn around the tumor on transaxial PET images of
the baseline and post-treatment scans, and a volume of
interest was determined using an automated isocontour-
ing program [23, 24]. The maximum SUV (SUVmax)
within the tumor volume of interest was then registered
for each study. Finally, the percentage change of the 18F-
FDG uptake in the post-treatment scan relative to base-
line scan was determined for each animal. All quantita-
tive data from animal imaging studies were expressed as
mean ± SE.
Analysis of excised tumors
After treatment, tumors were surgically removed, imme-
diately frozen in liquid nitrogen, and stored at −80 °C
until used. Tumor samples (at least three for each ani-
mal model and each treatment) were homogenized on
ice in RIPA lysis buffer with protease and phosphatase
inhibitors (Sigma-Aldrich) using a dounce homogenizer
followed by passages through a 26-gauge needle. The
suspension was clarified by centrifugation at 13,000×g
for 30 min at 4 °C and subjected to western blot analysis
using a standard procedure.
Since in a previous study [16] we showed that inhib-
ition of EGFR signaling in NSCLC cells reduces aerobic
glycolysis and restores oxidative phosphorylation through
the concerted downregulation of HKII and p-PKM2
Tyr105 and upregulation of mitochondrial complexes
(OXPHOS), we tested the levels of these selected markers
of energy metabolism in tumors from untreated and
treated animals. Antibodies used for western blotting in-
cluded mouse monoclonal antibodies against actin
(Sigma; 1 μg/mL) and α-tubulin (Sigma; 1 μg/mL), and
the OXPHOS cocktail (Mitoscience, Eugene, OR; 1:1000)
that targets the following proteins: 20-kD subunit of
Complex I (20 kD), COX II of Complex IV (22 kD), 30-
kD Ip subunit of Complex II (30 kD), core 2 of Complex
III (~50 kD), and F1α (ATP synthase) of Complex V
(~60 kD); rabbit monoclonal antibody against PKM2
(Cell Signaling; 0.1 mg/mL); and rabbit polyclonal anti-
bodies against hexokinase II (Cell Signaling; 1:1000),
phospho-PKM2 Tyr105 (Cell Signaling; 1:1000), cyclin
D1 (Cell Signaling; 1:1000), and PGC-1α (Santa Cruz
Biotechnology, 1:1000). A commercially available ECL kit
(GE Healthcare, UK) was used to reveal the reaction.
The western blotting signal was then quantified by
morphodensitometric analysis using ImageJ software
(NIH, Bethesda, MD, USA). Briefly, the product of the
area and the optical density of each band were deter-
mined and normalized to the same parameter derived
from the actin control. Data were expressed as relative
protein levels of each treated sample compared to the
corresponding vehicle-treated internal control.
Statistical analysis
Statistical analysis was done using the software MedCalc
for Windows, version 12.7.0.0 (MedCalc Software,
Fig. 1 Representative scheme of treatment in H1975- and H1993-tumor-
bearing animals. NSCLC animal models of T790M-mediated resistance
(H1975) were treated by oral gavage with 50 mg/kg erlotinib, WZ4002,
or vehicle whereas mice bearing xenografts with MET amplifica-
tion (H1993) were treated with 50 mg/kg erlotinib, crizotinib, or vehicle.
Treatment was started 3 h after the baseline 18F-FDG PET/CT scan on
day 1 and was stopped 3 h before post-treatment scan on day 3
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Mariakerke, Belgium). Unpaired or paired Student’s t test
was used when appropriate to compare means. In particu-
lar, a paired t test was used to compare 18F-FDG uptake in
the same tumors before and after treatment, whereas an
unpaired t test was used to examine differences between
untreated controls and treated groups. Differences between
means were considered statistically significant for p < 0.05
(*) and highly statistically significant for p < 0.01 (**).
Results
To test whether H1975 and H1993 tumors were resist-
ant to erlotinib and to demonstrate that animal treat-
ment with WZ4002 or crizotinib could overcome
T790M-mediated resistance or MET amplification, re-
spectively, we determined the levels of cyclin D1, one of
the terminal mediators of EGFR signaling pathways, in
untreated and treated tumor-bearing animals (Fig. 2).
Both short- (3 days) and long-term (9 days) treatment
with erlotinib did not cause any significant change of
cyclin D1 levels indicating resistance of H1975 (Fig. 2a)
and H1993 (Fig. 2b) tumors to first-generation EGFR
TKIs. Conversely, a strong reduction of cyclin D1 levels
was observed after treatment of animals bearing H1975 or
H1993 tumors with WZ4002 or crizotinib, respectively.
Since short-term treatment with 50 mg/kg inhibitors did
not cause any significant changes in tumor volume (data
not shown), long-term studies were performed with high-
dose treatment to confirm that H1975 (Fig. 3a) and
H1993 (Fig. 3b) tumors were resistant to erlotinib and
sensitive to WZ4002 or crizotinib, respectively.
Imaging studies of nude mice bearing H1975 and H1993
xenografts were performed with 18F-FDG PET/CT before
and after 3 days treatment with different inhibitors or ve-
hicle. All tumors were detected in the baseline 18F-FDG
scan, and the SUVmax values obtained from pre- and post-
treatment imaging studies are shown in Fig. 4a. The per-
centage variations of 18F-FDG uptake in post-treatment im-
aging studies compared with the corresponding baseline
scans are shown Fig. 4b. In the H1975 xenografts, WZ4002
treatment caused a reduction of 25.87 % ± 8.93 % in 18F-
FDG uptake (n = 4; p = 0.02) whereas the administration of
erlotinib was followed by an increase of 23.51 % ± 9.72 %, a
value not statistically different (n = 4; p = 0.49) from that
found in vehicle-treated animals but significantly higher
than that observed in WZ4002-treated mice (p = 0.01). In
the H1993 xenografts, 18F-FDG uptake was reduced by
14.70 % ± 1.30 % (n = 4; p = 0.003) after treatment with cri-
zotinib and by 18.40 % ± 9.19 % (n = 4; p = 0.13) in response
to erlotinib. These values were significantly lower than that
found in vehicle-treated animals (p = 0.006 vs erlotinib; p =
0.0006 vs crizotinib) indicating that both drugs reduce glu-
cose consumption in H1993 tumors despite their resistance
to erlotinib.
Representative PET transaxial images showing the dif-
ferential metabolic response to erlotinib in H1975- and
H1993-resistant xenografts are shown in Fig. 4c. As ex-
pected, the 18F-FDG uptake increased in H1975, tumor-
bearing mice treated with erlotinib, whereas tracer uptake
decreased in the H1993 xenografts after treatment with
erlotinib. Therefore, the 18F-FDG uptake can be consid-
ered an early reliable biomarker of T790M-mediated re-
sistance to erlotinib and sensitivity to third-generation
EGFR TKIs. Conversely, in models of MET amplification,
the 18F-FDG uptake does not reliably reflect this type of
resistance since modulation of glucose consumption and
proliferation appear to be uncoupled.
After imaging studies, tumors were surgically removed in
order to evaluate the expression levels of several key pro-
teins of glycolysis and subunits of mitochondrial complexes
(Fig. 5a, b). Figure 5a shows that a significant reduction of
HKII and p-PKM2 Tyr105 occurs in H1975 tumors in re-
sponse to WZ4002 as compared to untreated controls (n =
3; HKII, p = 0.03; p-PKM2 Tyr105, p = 0.04) or erlotinib-
treated animals (n = 3; HKII, p = 0.02; p-PKM2 Tyr105, p =
0.0097). In the H1993 xenografts, treatment with crizotinib
was followed by a significant reduction of HKII (n = 3; p =
0.03) and p-PKM2 Tyr105 (n = 3; p = 0.04) as compared to
untreated controls and no statistically significant differences
Fig. 2 Cyclin D1 levels in xenografts obtained from untreated and treated animals. a H1975- and b H1993-tumor-bearing animals were treated
for 3 or 9 days with 50 or 100 mg/kg erlotinib, WZ4002, crizotinib, or vehicle. Surgically removed tumors were homogenized and tested for levels
of cyclin D1, one of the main terminal mediators of EGFR signaling pathways, by western blot analysis at the indicated time and doses. Actin or
tubulin served to ensure equal loading
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in the levels of the two glycolytic proteins were found be-
tween crizotinib- and erlotinib-treated animals (HKII, p =
0.73; p-PKM2 Tyr105, p = 0.34).
A parallel strong upregulation of mitochondrial com-
plexes (subunits I–IV) was observed in H1975 tumors in
response to WZ4002 as compared to vehicle- and
erlotinib-treated animals (n = 3; p < 0.05 for all subunits)
(Fig. 5b). Similarly in H1993 tumors, treatment with cri-
zotinib caused a significant increase of OXPHOS levels
(n = 4; p < 0.01 for subunits I, III, and IV; p < 0.05 for
subunit II) as compared to vehicle-treated animals. Not-
ably, in the same animals, even treatment with erlotinib
caused a significant upregulation of mitochondrial com-
plexes (n = 4; p < 0.05 for subunits I, III, and IV) as com-
pared with vehicle-treated mice. In addition, levels of
PGC-1α, a transcriptional coactivator of mitochondrial
biogenesis, were increased after the treatment of H1975
and H1993 tumors with WZ4002 and crizotinib, respect-
ively, whereas erlotinib was effective only in H1993 tu-
mors (Fig. 6). These ex vivo findings taken together were
Fig. 3 Long-term tumor growth of NSCLC xenografts in untreated and treated animals. Tumor growth of a H1975 and b H1993 xenografts in animals
treated with 100 mg/kg of erlotinib, WZ4002, crizotinib, or vehicle. Data are expressed as a percentage of tumor volume at day 1 considered as 100 %.
At each time point, significant differences versus vehicle-treated animals were indicated with *p < 0.05 and **p < 0.01 whereas the symbol # indicated
significant differences versus erlotinib-treated animals, p < 0.05
Fig. 4 Imaging studies and percentage variation of 18F-FDG uptake in nude mice bearing H1975 and H1993 xenografts. a SUVmax of H1975 and H1993
xenografts obtained from baseline and post-treatment scans are expressed as mean ± SE. b Percentage variations of 18F-FDG uptake in H1975- and H1993-
tumor-bearing animals in response to each treatment. Significant differences versus vehicle-treated animals were indicated with *p< 0.05, **p< 0.01, and
***p< 0.001; significant differences versus erlotinib-treated animals were indicated with #p< 0.05. c Representative transaxial 18F-FDG PET images of mice
before (left panels) and 3 days after (right panels) treatment with 50 mg/kg erlotinib in H1975 (upper panels) and H1993 (lower panels) xenografts
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in agreement with imaging results indicating that the re-
duction of aerobic glycolysis and the reactivation of oxi-
dative phosphorylation underlie early 18F-FDG changes
in response to EGFR inhibition.
Discussion
The present study showed that 18F-FDG PET/CT is able
to detect T790M-mediated resistance to EGFR inhibitors
but it fails to identify MET amplification as a cause of re-
sistance in NSCLC. An early reduction of 18F-FDG up-
take was observed in H1975 tumors bearing the T790M
mutation after treatment with WZ4002 but not with erlo-
tinib. Conversely, in H1993 tumors, harboring MET amp-
lification, 18F-FDG uptake was significantly reduced after
treatment with both crizotinib and erlotinib despite the
fact that they were resistant to erlotinib. In agreement
with in vivo findings, a reduction of key glycolytic en-
zymes and an upregulation of OXPHOS were found in
H1975 tumors only after treatment with WZ4002 whereas
H1993 tumors showed a reduction of HKII and p-PKM2
Tyr105 as well as an increase of mitochondrial complexes
after treatment with both crizotinib and erlotinib.
Previous studies with 18F-FDG PET/CT in erlotinib-
naïve NSCLC patients showed that an early reduction of
18F-FDG uptake predicts morphovolumetric tumor re-
sponse and correlates with longer PFS and OS [11, 12].
Our findings are in agreement with these observations
by showing that effective inhibition of EGFR signaling
pathways reduces 18F-FDG uptake as early as 3 days
after initiation of therapy. Additional insights were also
provided on the mechanisms modulating glucose metab-
olism in resistant tumors exposed to erlotinib showing
that when resistance is due to redundant lateral signal-
ing, the proliferation pathways remain constantly active
whereas the glycolytic cascade is inhibited and accom-
panied by a PGC-1α-dependent upregulation of mito-
chondrial complexes.
Fig. 5 Tumor levels of glycolytic enzymes and OXPHOS in H1975 and H1993 xenografts. Surgically removed H1975 and H1993 tumors were homogenized
and tested for levels of key glycolytic proteins (a) and subunits of mitochondrial complexes (b) by western blot analysis in response to each treatment. The
bands were quantified by morphodensitometric analysis using ImageJ software. Data are expressed as relative protein levels of each treated sample
compared to the corresponding vehicle-treated internal control. Significant differences versus vehicle-treated animals were indicated with *p< 0.05, **p< 0.01;
significant differences versus erlotinib-treated animals were indicated with #p< 0.05 and ##p< 0.01
Fig. 6 PGC-1α levels in xenografts obtained from untreated and
treated animals. Levels of PGC-1α were determined in H1975 and
H1993 excised tumors in response to the indicated treatment. Actin
served to ensure equal loading
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In particular, the reduction of HKII levels in response
to EGFR inhibition causes a decrease of glucose mole-
cules entering the glycolytic cascade and a parallel re-
duction of 18F-FDG phosphorylation and tracer
entrapment. PKM2 is another key glycolytic enzyme that
catalyzes the conversion of phosphoenolpyruvate to
pyruvate. High levels of PKM2 are found in a variety of
human tumors including lung, breast, and colon cancer
[25], and PKM2 is reported to exist as a low-activity di-
meric or high-activity tetrameric form depending on the
phosphorylation status of the enzyme at Tyr105 residue
[26]. In the dynamic equilibrium between the two forms,
the active tetrameric enzyme is favored by Tyr105 de-
phosphorylation. Therefore, it is conceivable that the re-
duction of p-PKM2 Tyr105 levels in response to EGFR
inhibitors promotes tetramer formation and a high en-
zymatic catalytic activity in NSCLC that in turn may re-
direct pyruvate flux toward mitochondrial oxidative
phosphorylation [27]. In agreement with these observa-
tions, OXPHOS levels were upregulated in animal
models of T790M-mediated resistance after treatment
with WZ4002 and in xenografts with MET amplification
after therapy with erlotinib or crizotinib. Therefore, tu-
mors that are resistant due to MET amplification are still
able to switch energy metabolism from aerobic glycolysis
to oxidative phosphorylation independently from the
persistently high proliferation rate. As shown in our pre-
vious study in NSCLC cells, the metabolic switch from
glycolysis to oxidative phosphorylation is not compensa-
tory but the result of the fine tuning of the AKT and
ERK1/2 pathways in NSCLC cells [16].
Our findings taken together may have many clinical im-
plications for NSCLC patients receiving EGFR-targeted
therapy and undergoing 18F-FDG PET/CT to monitor
tumor response. In fact, the persistently high 18F-FDG up-
take after therapy is a reliable imaging biomarker of tumor
resistance whereas the early reduction of tracer uptake
during treatment does not univocally indicate tumor
sensitivity to EGFR inhibitors since glucose metabolism
and proliferation may be differently regulated depending
on the cellular context. Previous studies indicated that
18F-FDG uptake may identify early in the course of treat-
ment NSCLC patients who may or may not benefit from
treatment with EGFR TKIs [28]. This holds true for the
majority of erlotinib-naïve NSCLC patients who have
tumors with a low probability to be resistant. In erlotinib-
treated patients, the possibility that the 18F-FDG uptake
does not reflect sensitivity to EGFR TKIs should be taken
into account especially when resistance is clinically
suspected.
Conclusions
In conclusion, 18F-FDG uptake is a reliable imaging bio-
marker of T790M-mediated resistance and its reversal in
NSCLC whereas it may not be accurate in the detection
of MET-mediated resistance. When resistance to EGFR
TKIs is due to redundant lateral signaling, the proliferation
pathways remain constantly active while an early metabolic
switch from aerobic glycolysis to oxidative phosphorylation
may occur in resistant tumors reducing their dependence
from external glucose supply and tracer uptake.
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